Big Tobacco's New Year's Resolution to Quit Smoking.

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.k79

2018-01-01

BMJ

Abstract:A tobacco company claims it wants to stop selling cigarettes in the UK—and is developing other ways to keep people taking nicotine. Nigel Hawkes reports

What problem does this paper attempt to address?

Breaking bad habits

M. Tolba

2008-10-08

Abstract:This month marks the 50th anniversary of the landmark US Surgeon General’s report linking cigarette smoke to lung cancer. Yet despite the endless antismoking campaigns, medical research documenting tobacco’s caustic health effects, and litigation against cigarette makers that has surged since that time, the rewarding and euphoric effects of nicotine keep more than 1 billion smokers worldwide craving their next puff.

Medicine,Psychology
Pursuing a smoke-free generation

Lawrence O. Gostin

DOI: https://doi.org/10.1126/science.adq5006

IF: 56.9

2024-05-25

Science

Abstract:The United Kingdom may soon become a world leader in forging a smoke-free generation. Last month, the country passed a bill that bans the sale of cigarettes to anyone born in 2009 or later. The prime minister claims the policy will "phase out smoking in young people almost completely as early as 2040." A final vote by Parliament is expected next month. Tobacco claims 8 million lives every year, and could claim a billion lives over this century—mostly in low- and middle-income countries. For every person that dies, at least 30 more suffer from smokingrelated chronic disease. The benefits of a tobacco-free society would be transformational.

multidisciplinary sciences
Achieving a smoke-free country—a best buy for the UK chancellor

Nick Hopkinson,Sanjay Agrawal,Ranee Thakar,Charmaine Griffiths,Ian Walker,J Robert Branston

DOI: https://doi.org/10.1136/bmj.q2231

2024-10-17

BMJ

Abstract:The UK government has set out a bold mission to improve the nation's health. This is an urgent and essential task, not just to improve individual wellbeing, but because poor health is a huge drain on the economy. The mission will require action across all arms of government. Unless smoking is tackled,1 there is no prospect of delivering on Labour's manifesto commitment to halve the gap in healthy life expectancy between the richest and poorest regions.2 We therefore urge the chancellor to use the budget on 30 October to invest in creating a smoke-free UK as quickly as possible and make the tobacco industry pay.The rationale for investing to end the tobacco epidemic could not be stronger. The annual cost of smoking to individuals, public services, and the wider UK economy is £93bn. The direct cost of smoking to the UK public finances in 2023 was £21.9bn, with a net...

medicine, general & internal
Pharmaceuticalisation as the tobacco industry’s endgame

Yogi Hale Hendlin,Elieen Le Han,Pamela M. Ling

DOI: https://doi.org/10.1136/bmjgh-2023-013866

IF: 8.056

2024-02-01

BMJ Global Health

Abstract:Context Declining smoking prevalence and denormalisation of tobacco in developed countries reduced transnational tobacco company (TTC) profit during 1990s and 2000s. As these companies faced increasingly restrictive policies and lawsuits, they planned to shift their business to socially acceptable reduced-harm products. We describe the internal motivations and strategies to achieve this goal. Methods We analysed previously secret tobacco industry documents available through the Truth Tobacco Documents Library. These documents were triangulated with TTCs’ investor and other professional reports, websites and public statements. Findings Mimicking pharmaceutical business models, tobacco companies sought to refurbish their image and ensure long-term profitability by creating and selling pharmaceutical-like products as smoking declined. These products included snus, heated tobacco products, e-cigarettes, nicotine gums and inhalers. Tobacco companies created separate divisions to develop and roll out these products, and the majority developed medical research programmes to steer these products through regulatory agencies, seeking certification as reduced-harm or pharmaceutical products. These products were regarded as key to the survival of the tobacco industry in an unfriendly political and social climate. Conclusions Pharmaceuticalisation was pursued to perpetuate the profitability of tobacco and nicotine for tobacco companies, not as a sincere search to mitigate the harms of smoking in society. Promotion of new pharmaceuticalised products has split the tobacco control community, with some public health professionals and institutions advocating for the use of ‘clean’ reduced-harm nicotine and tobacco products, essentially carrying out tobacco industry objectives.

public, environmental & occupational health
Ensuring a safe, tobacco free future for the young: protecting children from tobacco industry interference

Assunta,M.,Chamberlain,P.

DOI: https://doi.org/10.1136/tc-2024-058698

IF: 6.953

2024-04-19

Tobacco Control

Abstract:The tobacco industry needs to replace the eight million people who use tobacco1 and die every year from tobacco-related diseases. These are often recruited among the young, since 9 out of 10 people who smoke start before the age of 18.2 Young customers keep the industry viable. The WHO estimates over 40 million children aged 13–15 years use tobacco.3 While most governments have implemented measures to protect minors from tobacco use in accordance with the WHO Framework Convention on Tobacco Control (FCTC), the fight to protect the young remains intense as the tobacco industry continues to target youth. The tobacco industry is 'inordinately profitable'4; the profits of the six largest tobacco companies in 2018 were US$55 billion, more than Coca Cola, PepsiCo, Nestle, Mondelez, FedEx, General Mills, Starbucks, Heineken and Carlsberg combined.5 6 In the USA alone, in...

public, environmental & occupational health,substance abuse
Any plan to make smoking obsolete is the right step

DOI: https://doi.org/10.1038/d41586-024-01176-4

IF: 64.8

2024-04-24

Nature

Abstract:The United Kingdom is correct to attempt to end the single largest preventable cause of illness and death, as was New Zealand before its government changed its mind. The United Kingdom is correct to attempt to end the single largest preventable cause of illness and death, as was New Zealand before its government changed its mind.

multidisciplinary sciences
Hostage to fortune: an empirical study of the tobacco industry's business strategies since the advent of e-cigarettes

Marisa de Andrade,Kathryn Angus,Gerard Hastings,Nikolina Angelova

DOI: https://doi.org/10.1080/09581596.2018.1552778

2018-12-18

Abstract:The tobacco market has been transformed by the arrival of e-cigarettes and array of alternative nicotine delivery systems (ANDS). Public health has struggled to cope with these changes and clear divisions are apparent, but less is known about the tobacco industry (TI) response. This first empirical study to examine TI and independent ANDS companies' business strategies fills this gap. Primary data were collected through 28 elite interviews with senior/influential TI and independent stakeholders, triangulated with a documentary analysis of company reports, investor analyses, market research, and consultation responses (1022 documents). A deliberately emic analysis shows that tobacco multinationals were initially disconcerted by ANDS, but logic provided by the fiduciary imperative is enabling them to turn a potential threat into profitable opportunities. Interviewees argue market changes played to their strengths: customer links, expertise in nicotine, and enormous financial resources. This enabled portfolio diversification in which combustible and ANDS coexist; providing potential to develop robust scientific and regulatory positions and hope of retrieving corporate reputations. The principal threat for major tobacco players comes from the independent sector, which is prepared and able to satisfy bespoke consumer needs. Multinationals by contrast need to turn ANDS into a genuinely mass-market product appealing to its global customers. They are making progress. Given the continued buoyancy of the combustibles market, they have extensive resources to continue their efforts. Disruptive innovations are not unique to tobacco control. Equivalent technological solutions - with concomitant business opportunities - are emerging in obesity and alcohol fields with implications for public health.
["Nicotine industry: risk reduction,an exclusively financial objective"]

Yves Martinet,Emmanuelle Béguinot,Pascal Diethelm,Nathalie Wirth

Abstract:Nicotine industry: harm reduction, an exclusively financial objective The knowledge of tobacco smoking health effects, combined with the implementation of measures efficient on its use, leads to tobacco sale reduction with tobacco industry financial losses that, in order to survive, has to recruit new young consumers, and maintain current smokers' use. The industry promotes a new way for tobacco use that, according to it, would reduce harm: heat-not-burn tobacco. But, there is currently no independent scientific proof for such a harm reduction. In the meantime, it promotes a confusion among electronic cigarettes and heat-not-burn tobacco. Heat-not-burn tobacco is promoted via foundations, NGOs, prestigious third parties, mechanic sports financing, and publicity with a strong marketing targeting young people through social networks. The current French regulation concerning smoked tobacco, including plain pack and high taxes, doesn't apply on heat-not-burn tobacco.
Zonnic®: a new player in an old field

Min Gong,Michael S Dunbar,Claude Setodji,William G Shadel

DOI: https://doi.org/10.1186/s13011-017-0124-3

2017-09-06

Abstract:The tobacco industry is continually evolving to adapt to increasing tobacco control pressure and regulation, and to cater to consumer preferences. Recently, RJ Reynolds rolled-out a nicotine-containing gum, Zonnic®, which is marketed as a smoking cessation and reduction product and is sold at convenience stores at a lower price and in a smaller quantity than existing brands sold at pharmacies. The introduction of Zonnic® products is a critical first step in tobacco industry's involvement in the NRT market and a serious indication of the evolving tobacco and nicotine-delivery industry and environment. It is likely that this trend will continue and spread, and as such, have a significant impact at multiple dimensions, including consumer perceptions and behavior, tobacco and NRT industry business strategy, and regulation and policy. In this special communication, we present an overview of the current marketing strategy for Zonnic®, discuss its potential impacts at the market level and at the level of the individual consumer, and suggest research and policy priorities based on the magnitude and urgency of the impacts.
Electronic Cigarettes for Smoking Cessation — Have We Reached a Tipping Point?

Nancy A. Rigotti

DOI: https://doi.org/10.1056/nejme2314977

IF: 158.5

2024-02-16

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 7, Page 664-665, February 2024.

medicine, general & internal
Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of Competition

David T Levy,Frances Thirlway,David Sweanor,Alex Liber,Luz Maria Sanchez-Romero,Rafael Meza,Clifford E Douglas,K Michael Cummings

DOI: https://doi.org/10.1093/ntr/ntad014

2023-11-22

Abstract:Introduction: Some cigarette companies have started to talk about replacing cigarettes with less harmful alternatives, which might include nicotine vaping products (NVPs), heated tobacco products (HTPs), and oral nicotine delivery products. We consider market competition as a primary driver of whether cigarette companies follow through on their stated intentions. Aims and methods: We focus on the behavior of cigarette companies in the United States. We compare competition in the pre- and post-2012 time periods, analyze the impact of the growth in NVPs on smoking prevalence and cigarette company profits, and examine the potential future role of competition. Results: Since 2006, consumers have broadened their use of non-combustible nicotine delivery products (NCNDPs) to include, inter alia, NVPs, HTPs, and oral nicotine pouches. U.S. cigarette companies have acquired major stakes in each of these product categories which corresponds to a period of rapidly declining adult smoking prevalence, especially among younger adults (ages 18-24 years). The shifting dynamics of the nicotine product marketplace are also reflected in cigarette company stock prices. While cigarette companies are likely to promote HTPs and nicotine delivery products over NVPs, their incentives will be directly related to competition from independent firms, which in turn will depend on government regulation. Conclusions: Although cigarette companies will back alternatives to combusted tobacco when threatened by competition, the prospects for their lasting conversion to NCNDPs will depend on the extent of such competition, which will be influenced by government regulation of tobacco products. Implications: Regulations that limit competition from independent firms while also protecting cigarette company profits risk slowing or even reversing recent declines in smoking, especially among youth and young adults. Regulations that reduce the appeal and addictiveness of combusted tobacco products, such as higher cigarette taxes or a reduced nicotine standard, will encourage smokers to quit and/or switch to less harmful non-combusted forms of tobacco. The regulation of non-combustible nicotine delivery products and cigarettes should be proportionate to their relative risks, so that smokers have incentives to switch from combustibles to safer alternatives, and cigarette companies have incentives to promote safer products.
Duty of care? Tobacco laws and doctors in parliament

Towns,C.,Brockway,B.,Jackson,C.,Burgess,S.

DOI: https://doi.org/10.1136/tc-2024-058983

IF: 6.953

2024-10-19

Tobacco Control

Abstract:Introduction Medicine is a social science and politics is nothing more than medicine on a larger scale. —Virchow New Zealand received international attention in 2022 when it passed legislation to end tobacco sales to those born after 2008, essentially creating a smoke-free generation (defined as less than 5% of people smoking). The approach would also have decreased the amount of nicotine in cigarettes to non-addictive levels and dramatically decreased the number of retail outlets. The plan had cross-party support including that of the major opposition party (National) which had adopted the 2025 smoke-free goal and supported the subsequent specific measures.1 The UK government's plan to introduce similar legislation suggests this approach to be at the vanguard of antitobacco laws internationally. However, a change of government (a coalition of National and two smaller parties) resulted in repeal in 2024, hence New Zealand becomes the latest country—following...

public, environmental & occupational health,substance abuse
Tobacco Bill: Banning smoking in certain outdoors spaces is welcomed, but cessation services must not be forgotten

Jacqui Wise

DOI: https://doi.org/10.1136/bmj.q2443

2024-11-06

BMJ

Abstract:Plans to ban smoking outside schools and hospitals in England have been broadly welcomed, but experts and charities say there is still an urgent need for investment in NHS stop smoking services.The main focus of the updated Tobacco and Vapes Bill, laid before Parliament on 5 November, is to make it illegal to sell tobacco products to anyone born on or after 1 January 2009, with the aim of creating the first smokefree generation.1 The bill completed committee stage in the last parliament. The new bill goes further than the last one by giving the government powers to extend the indoor smoking ban to specific outdoor spaces, with children's playgrounds, areas outside schools, and hospitals all being considered, subject to consultation.However, the government has dropped plans to outlaw smoking outside pubs and restaurants, after an outcry from the hospitality industry.The new bill will also ban advertising and sponsorship of vapes...

medicine, general & internal
E-cigarettes Work Better Than Nicotine Replacement and Willpower to Help People Quit Smoking

Nigel Hawkes

DOI: https://doi.org/10.1136/bmj.g3419

2014-01-01

BMJ

Abstract:Electronic cigarettes could substantially improve public health by making it easier for smokers to quit, concludes a new study that showed a 60% higher quit rate among e-cigarette users than among smokers who relied on willpower alone or nicotine replacement treatments bought over the counter. The findings are likely to add fuel to the debate over whether e-cigarettes are a force for good (by helping people give up real cigarettes) or for evil (because they “renormalise” the activity of smoking). Robert West, professor of health psychology and director of tobacco studies at University College London, a coauthor of the study, came down firmly in the first camp at a briefing in London on the publication of the study in Addiction .1 “There is no evidence at all of …
A brief overview of the tobacco industry in the last 20 years

Stella Aguinaga Bialous,Silvy Peeters

DOI: https://doi.org/10.1136/tobaccocontrol-2011-050395

Abstract:Since the launch of Tobacco Control 20 years ago, there have been several changes in the tobacco industry worldwide. The goal of this commentary is to present some of the keys changes of the past two decades. This time is marked by mergers and acquisitions that led to the existence, today, of four major transnational tobacco companies: Philip Morris International, British American Tobacco, Japan Tobacco and Imperial Tobacco. The possible role of the China National Tobacco Corporation in the world tobacco market is also discussed. In addition, in the past decade there was an increase in tobacco companies' investment in non-cigarette forms of nicotine delivery. The impact of these changes for tobacco control policy is briefly discussed.
Evaluating tobacco industry 'transformation': a proposed rubric and analysis

Richard Edwards,Janet Hoek,Nancy Karreman,Anna Gilmore

DOI: https://doi.org/10.1136/tobaccocontrol-2021-056687

Abstract:Some tobacco companies claim they are 'transforming' by adopting harm reduction goals or even seeking to achieve a 'smokefree' world. What characterises transformation and whether companies can or are transforming is unclear. Nevertheless, such claims are gaining traction. We critically investigated tobacco industry transformation by exploring the definition and criteria for evaluating transformation, and assessed whether transformation is occurring and feasible.Companies' transformation claims centre on increasing sales of new tobacco and nicotine products like e-cigarettes ('new products') with little attention to reducing sales of more hazardous smoked and oral products ('conventional products').We define a transforming tobacco company as one demonstrating substantial, rapid and verifiable progress towards eliminating the production and sale of conventional tobacco products within 5 years in all markets where it operates.We found no evidence any tobacco company is meeting the three essential criteria of rapidly progressing towards eliminating conventional products, ceasing to obstruct effective tobacco control measures and taking action to minimise smoking uptake and disparities. While some companies are developing new product portfolios, their actions are more consistent with profit maximisation than eliminating conventional product use. This approach is best described as 'pseudo-transformation', designed to delay implementation of effective tobacco control policies. In addition, our analysis suggests replacing conventional products with new nicotine products is unlikely to be a viable long-term business model.Public health practitioners should not rely on tobacco industry claims but should lead the transformation debate, establish credible definitions and criteria, and monitor and assess whether transformation is occurring.
The failure of the UK to tax adequately tobacco company profits

J Robert Branston,Anna B Gilmore

DOI: https://doi.org/10.1093/pubmed/fdz004

2020-02-28

Abstract:Background: A key driver of the global tobacco epidemic is the massive profit earned from manufacturing tobacco products despite high levels of product taxation. Two of the four major Transnational Tobacco companies are based in the UK, where there is growing evidence of corporate tax avoidance by transnational firms and where there are calls for the industry to pay more towards the harms caused by tobacco products. Objectives/methods: UK tobacco company profit and corporation tax data between 2009 and 2016 is obtained from publically available sources. The intention is not to perform a piece of forensic accounting but to establish the broad pattern of profit and taxation in order to inform consideration of tobacco product and firm taxation, and hence public health. Results: Very little profit based taxation has been paid in the UK despite high levels of reported profits, both in the domestic market and globally. Conclusions: The UK needs better reporting and corporate taxation standards. Tobacco companies should be made to pay more profit based taxation, such as by extending the surcharge on corporation tax currently paid by UK banks, and by making sure companies pay appropriate taxes when reorganizing corporate structures.
Electronic Nicotine-Delivery Systems for Smoking Cessation

Reto Auer,Anna Schoeni,Jean-Paul Humair,Isabelle Jacot-Sadowski,Ivan Berlin,Mirah J. Stuber,Moa Lina Haller,Rodrigo Casagrande Tango,Anja Frei,Alexandra Strassmann,Philip Bruggmann,Florent Baty,Martin Brutsche,Kali Tal,Stéphanie Baggio,Julian Jakob,Nicolas Sambiagio,Nancy B. Hopf,Martin Feller,Nicolas Rodondi,Aurélie Berthet

DOI: https://doi.org/10.1056/nejmoa2308815

IF: 158.5

2024-02-16

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 390, Issue 7, Page 601-610, February 2024.

medicine, general & internal
'The last line of marketing': Covert tobacco marketing tactics as revealed by former tobacco industry employees

Christina Watts,Suzan Burton,Becky Freeman

DOI: https://doi.org/10.1080/17441692.2020.1824005

Abstract:In countries with bans on tobacco advertising and promotion, tobacco companies have focused their promotional expenditure on business-to-business relationship marketing activities aimed at retailers. However, evidence of such activities has been obtained through secondary sources only, including surveys and interviews with tobacco retailers and analyses of tobacco industry documents. To understand the breadth of promotional strategies employed in the retail sector to enhance tobacco sales, 10 semi-structured interviews were conducted with a sample of key informants who formerly worked for tobacco companies operating in Australia. A qualitative iterative approach was used to develop a thematic analysis of tobacco brand promotion and retailer marketing. Participants described tobacco retail marketing and promotion strategies that were categorised into three primary themes: (1) the provision of financial incentives, such as price promotions, cash payments and rebates; (2) the provision of experiential incentives, such as all-expenses paid vacations, exclusive parties and events, and (3) targeted marketing and education, which enabled retailers to market to consumers on behalf of tobacco companies. Such strategies had the ultimate objective of increasing market share and driving sales. For countries to comprehensively restrict all tobacco marketing, legislation must be introduced to outlaw these activities in tobacco advertising and promotion legislation.
New Zealand Smokers' Perceptions of Tobacco Endgame Measures: A Qualitative Analysis

Ivana Barbalich,Coral Gartner,Richard Edwards,Janet Hoek

DOI: https://doi.org/10.1093/ntr/ntab161

2022-01-01

Abstract:Introduction: New Zealand's equity-focused endgame goal (Smokefree 2025) aims to reduce smoking prevalence to minimal levels (ie, <5%) in all population groups by 2025. Inadequate progress has stimulated discussion of innovative measures to reduce prevalence; because few studies have explored how marginalized groups perceive these measures, we addressed this knowledge gap. Aims and methods: In November and December 2020, we conducted 20 in-depth interviews with people who smoked daily, were aged between 21 and 53, earned less than the median income (NZD33 900), and had marginal or inadequate income sufficiency. We explored participants' smoking history and used an elicitation exercise to probe their views on smokefree policies, including potential endgame measures. We used qualitative descriptive analysis and reflexive thematic analysis to interpret the data. Results: Participants favored increasing personal support to quit and reducing nicotine levels in cigarettes, but generally opposed tobacco excise tax increases and paying people to quit. While many privileged their right to "choose," some recognized that stronger policies could restore the loss of agency addiction caused. Participants felt smoking's powerful addictiveness remained poorly understood, and called for smoking to be recognized and treated as an addiction. Conclusions: Several participants supported intensifying existing measures or introducing new measures. However, their use of tobacco industry rhetoric to frame smoking as a choice they had made could inadvertently reinforce the stigma they experienced. Reframing cigarettes as an addictive product engineered by a deceptive industry, may make it easier for participants to access the expanded support and compassion they sought. Implications: Policy measures, such as reducing the nicotine level in cigarettes, could support endgame goals; however, greater public understanding of addiction is needed to reduce stigma, support self-efficacy, and foster smoking cessation. Industry denormalization campaigns could challenge views of smoking as a personal choice, decrease self-blame among people who smoke, and present endgame goals as likely to enhance agency.

Big Tobacco's New Year's Resolution to Quit Smoking.

Breaking bad habits

Pursuing a smoke-free generation

Achieving a smoke-free country—a best buy for the UK chancellor

Pharmaceuticalisation as the tobacco industry’s endgame

Ensuring a safe, tobacco free future for the young: protecting children from tobacco industry interference

Any plan to make smoking obsolete is the right step

Hostage to fortune: an empirical study of the tobacco industry's business strategies since the advent of e-cigarettes

["Nicotine industry: risk reduction,an exclusively financial objective"]

Zonnic®: a new player in an old field

Electronic Cigarettes for Smoking Cessation — Have We Reached a Tipping Point?

Do Tobacco Companies Have an Incentive to Promote "Harm Reduction" Products?: The Role of Competition

Duty of care? Tobacco laws and doctors in parliament

Tobacco Bill: Banning smoking in certain outdoors spaces is welcomed, but cessation services must not be forgotten

E-cigarettes Work Better Than Nicotine Replacement and Willpower to Help People Quit Smoking

A brief overview of the tobacco industry in the last 20 years

Evaluating tobacco industry 'transformation': a proposed rubric and analysis

The failure of the UK to tax adequately tobacco company profits

Electronic Nicotine-Delivery Systems for Smoking Cessation

'The last line of marketing': Covert tobacco marketing tactics as revealed by former tobacco industry employees

New Zealand Smokers' Perceptions of Tobacco Endgame Measures: A Qualitative Analysis